MedTrace Logo

Safety of Testosterone Undecanoate i.m. in Hypogonadal Men

NCT00452322 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2007-03-27

No results posted yet for this study

Summary

Treatment of male hypogonadism by testosterone substitution has be monitored in terms of safety. This study relates to safety of a new long-acting preparation.

Conditions

  • Hypogonadism

Interventions

DRUG

Testosterone Substitution by Testosterone Undecanoate i.m.

Sponsors & Collaborators

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Eberhard Nieschlag, MD, PhD · University Clinics Muenster, Germany

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-04-30
Completion
2007-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00452322 on ClinicalTrials.gov